Reneuron Share Discussion Threads

[norbus] 20/4/2015 09:41

No adverse effect is great, enough to speed the treatment to one injection into the brain; The main Q as to improvement to decide, is extent of improvement if any; If that is material, then Rene will be very valuable perhaps a X10 from here If improvement is pedestrian it will be a shame:disappointment will follow

[madengland] 20/4/2015 08:46

Surprised it looks like peeps are selling stock albeit small amounts..... This stock has great prospects

[bonzo] 17/4/2015 17:11

This is one of the most important news releases I have ever seen. It makes history. No other treatment has ever had a positive sustained outcome in stroke.

[madengland] 17/4/2015 15:52

Think it's still very much under the radar of many. And when it gets on peeps radar and they see Mr. Woodford holds 20%...... I think we could see a more than a few piling in

[stewart_25] 17/4/2015 14:43

Bigspuds - agreed - doesn't seem to move much even on great news!!!

[bigspuds] 17/4/2015 14:37

Never mind the papers. Let's see the price start to reflect the potential

[curlly] 17/4/2015 13:46

lets hope they put it in the papers over the weekend.

[norbus] 13/4/2015 08:07

SITIAIN

This now begins to look like a serious proposition; bit quiet on stroke, where some positive will finally set the share price free up a gradient; GL

[ftangftang] 13/4/2015 07:16

RNS Number : 9658J

ReNeuron Group plc

13 April 2015


13 April 2015 AIM: RENE

ReNeuron Group plc

("ReNeuron" or "the Company")

ReNeuron files application to commence Phase I/II clinical trial in the US with its stem cell therapy candidate for the blindness-causing disease, retinitis pigmentosa

Guildford, UK, 13 April 2015:ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that it has filed an Investigational New Drug (IND) application with the US FDA to commence a Phase I/II clinical trial with its human Retinal Progenitor Cell (hRPC)therapy candidate for retinitis pigmentosa (RP). RP is a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.

ReNeuron has worked with world-leading collaborators and academic institutions in the retinal disease field to successfully take its retinitis pigmentosa programme through pre-clinical development. These include the Schepens Eye Research Institute/Massachusetts Eye and Ear (an affiliate of Harvard Medical School), UCL Institute of Ophthalmology, Moorfields Eye Hospital and the US-based Foundation Fighting Blindness, the world's leading private source of research funding for inherited retinal diseases. The pre-clinical programme has also benefited from UK Government funding under a BioMedical Catalyst grant, awarded in 2013.

Pre-clinical studies carried out in disease models by the Company's academic collaborators have demonstrated that, when transplanted into the retina, ReNeuron's retinal progenitor cell technology has the potential to preserve existing photoreceptors, potentially reducing or halting further deterioration of vision. In addition, the progenitor cells have been shown to mature into functional photoreceptors that engraft into the photoreceptor layer, bringing the possibility of restored vision.

The proposed Phase I/II clinical trial will be conducted at Massachusetts Eye and Ear, Boston, a world-renowned clinical centre for the treatment of retinal diseases. The trial design is an open-label, dose escalation study to evaluate the safety, tolerability and preliminary efficacy of the hRPC stem cell therapy candidate in up to 15 patients with advanced RP. The method of administration of the hRPCs will be a single sub-retinal injection. The primary endpoint of the study is safety, with patients being followed up for 12 months post-treatment with monitoring including measurements of visual acuity.

Subject to regulatory and local ethics approvals, ReNeuron expects to be able to commence the clinical trial in the second half of this year. ReNeuron's cell therapy candidate for RP has been granted Orphan Drug Designation in both Europe and the US by the European Commission and the FDA, respectively. Orphan Drug Designation is typically granted to drug programmes that potentially provide significant benefit to patients with rare diseases that are life-threatening or chronically debilitating. In acknowledgment of the relatively small patient populations involved, commercial and other incentives are provided to developers of orphan drugs.

Dr Eric Pierce, Director, Retinal Degenerations Service at Massachusetts Eye and Ear, and Principal Investigator for the clinical trial, commented:

"We are pleased to be working with ReNeuron on this important Phase I/II clinical trial. The human Retinal Progenitor Cells being tested in the study are promising since they can make photoreceptors. The implanted cells may not only prevent degeneration of patients' vision but may possibly restore some vision by replacing degenerated photoreceptor cells. The work leading to this clinical trial began over 15 years ago in the laboratory of Michael Young PhD, de Gunzburg Scholar and Co Director of the Ocular Regenerative Medicine Institute at the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School."

Olav Hellebø, Chief Executive Officer of ReNeuron, commented:

"We are delighted to have progressed our hRPC stem cell therapy candidate for RP to the point of submitting an application to conduct a clinical trial in the US. Once approved and commenced, the proposed Phase I/II clinical trial in RP patients will be the third clinical study ongoing with ReNeuron's cell therapy candidates, alongside our Phase II clinical trial in stroke and our Phase I clinical trial in critical limb ischaemia. The proposed RP clinical trial initiates the Company's clinical activities in the US, a very significant milestone in the development of ReNeuron as a global leader in the stem cell therapy field."

cheers
ft ft

[madengland] 01/4/2015 13:10

Not good but not bad, necessarily.

[stewart_25] 01/4/2015 11:40

not sure how much good news this is....

[norbus] 01/4/2015 09:19

Such excitement at the management changes! More overheads sign of confidence or another funding round? Maybe both

[peawacks] 06/3/2015 17:21

My pleasure, mad !

[madengland] 06/3/2015 15:48

Nice to bump into an Amurite. Cheers mate.

[peawacks] 06/3/2015 14:57

Maybe this ?

[madengland] 06/3/2015 14:36

What's going on here then

[proactivest] 20/2/2015 13:59

Video Interview

UK based clinical stage stem cell business, Reneuron (LON:RENE) is moving ahead with its programme of clinical trials. The CFO, Michael Hunt, tells Proactiveinvestors that they are expecting results from its phase 2 trials of CTX for stroke victims by the end of 2015. With further data for its critical limb ischemia and retinitis pigmentosa trials expected in the early part of 2016.

hxxp://t.co/k8Sem5SdKr

[philip49] 04/2/2015 11:52

We still don't know who bought the 88,000,000 shares about time this was RNS'd don't you think, after all rules is rules and someone has to own up?!

[sitiain] 04/2/2015 06:44

Bit lasy here sorry,#
what are we actually expecting here news wise now.
Seems to have been ages since any patient news.
I assume with directors buying last week, no serious news on the immediate horizon

[stewart_25] 03/2/2015 16:19

my broker is showing 3.5 sell 4.0 buy

[21trader] 03/2/2015 16:08

3.87p paid looks pretty solid now. Good for 4p after that it is 50/50 if it climbs more looking at chart.